MAPLE GROVE, Minn., March 11, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a privately held, specialty pharmaceutical company committed to the development of new treatments for diseases of the central nervous system (CNS), is proud to sponsor emerging data for three investigational drug programs in epilepsy at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, CA, March 16-23, 2013.
Upsher-Smith's CNS pipeline consists of two Phase III programs: USL255 (topiramate), an investigational extended-release topiramate for the management of epilepsy in adults; and USL261 (midazolam) for the intranasal rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, often called seizure clusters. Additionally, USL260 (tonabersat) is a potential first-in-class neuronal gap junction modulator in Phase I of development for treatment of epilepsy.
"Upsher-Smith is committed to improving the lives of people living with epilepsy by developing innovative treatments to address the unmet needs of those who suffer from this condition," said William Pullman, MB BS, BMedSc, PhD, FRACP, Chief Scientific Officer, Upsher-Smith. "We are very pleased with the progress that has been made with each of our investigational CNS drug programs and are excited to share our ongoing scientific research in epilepsy at AAN's Annual Meeting."
Upsher-Smith sponsored posters include:
Single, High Doses of USL255, an Extended-Release Topiramate Formulation, Are Well Tolerated and Demonstrate a Dose-Proportional Pharmacokinetic Profile in Healthy Subjects Poster 04.212; Session P04: Epilepsy: Antiepileptic Medications: Special Populations and Pharmacokinetics; Wednesday, March 20, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
Safety and Pharmacodynamics of USL261, a Novel Formulation of Midazolam Optimized for Intranasal Administration P02.211; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
Pharmacokinetics of USL261, a Novel Formulation of Intranasal Midazolam Poster 02.212; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
Tonabersat, a Novel Investigational Anti-Seizure Drug, Inhibits Seizures in Models of Generalized Epilepsy Poster 02.209; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m. To schedule an interview with an investigator, please contact Elizabeth Likly at email@example.com.
Epilepsy is a medical condition that causes seizures affecting a variety of cognitive and physical functions. More than two million people in the U.S. are estimated to be affected by epilepsy with about 200,000 new cases of epilepsy diagnosed each year.1
Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded, branded-generic and generic pharmaceuticals. Upsher-Smith has a particular focus on providing therapies to assist people suffering from central nervous system diseases (including epilepsy, Parkinson's disease and Alzheimer's disease) and also markets products relating to cardiology, dermatology and women's health. In addition to products currently marketed, Upsher-Smith has an emerging neurology pipeline with three products in clinical development, two of which are in Phase III clinical trials. For more information, visit www.upsher-smith.com.
1. Epilepsy Foundation. About Epilepsy. Available at: http://www.epilepsyfoundation.org/aboutepilepsy/whatisepilepsy/statistics.cfm. Accessed February 4, 2013.
|SOURCE Upsher-Smith Laboratories, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. Innophos CFO To Present At 2013 Sidoti Emerging Growth Conference
2. Frost & Sullivan Recognizes Cytomedix for its Pioneering System that Supports the Emerging Regenerative Therapies Market
3. Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
4. The 113th Canton Fair: "Great Opportunities for Emerging Markets"
5. Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards Their Products
6. Cumberland Emerging Technologies Expands Life Sciences Center
7. Innovative CA Tumor Marker Tests Technologies and Emerging Markets
8. Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
9. Innovative Hematology and Flow Cytometry Technologies and Emerging Markets
10. Henry Schein Announces Featured Speakers For The "Recovery Empowerment Symposium: Emerging From The Storm"
11. Cepheid Announces Executive Vice President Emerging Markets
(Date:4/29/2016)... BERLIN , April 29, 2016 ... world-leading glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years ... pharmaceutical and biotechnology industries. His last role was at ... Member of the Executive Board. Previously Dr. Zurlo held ...
(Date:4/28/2016)... 2016 Marking its one year anniversary since ... cancer risk test, Color Genomics announced ... highly impact the most common hereditary cancers affecting ... Test analyzes hereditary cancer risks for breast, colorectal, ... The Color Test is physician ordered and includes ...
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life ... Pharmacovigilance team to bring a wealth of insight to a growing ... pharmacovigilance knowledge. George Phillips joined ArisGlobal in ... Breaking Medicine Technology:
(Date:4/29/2016)... ... , ... Our bodies are bombarded daily by environmental and lifestyle factors that ... is to adopt a more healthful diet, but too many people think that food ... Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees ...
(Date:4/29/2016)... , ... April 29, 2016 , ... On Tuesday, April ... across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the ... Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations which ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce ... stability, even security. Most importantly, employees are the single most important asset in ... workers so unhappy? , Just under half of American workers are emotionally checked ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ... Breaking Medicine News(10 mins):